InvestorsHub Logo
Followers 2
Posts 1472
Boards Moderated 0
Alias Born 07/20/2016

Re: samk post# 30456

Saturday, 08/19/2017 10:54:55 AM

Saturday, August 19, 2017 10:54:55 AM

Post# of 108192
Here's what I really am intrigued by, "The third poster presentation, "Identification of an intratumoral immune gene signature associated with tumor regression in an axalimogene filolisbac-treated murine HPV+ tumor model,” will include preclinical data regarding molecular biomarkers associated with tumor regression in a murine HPV+ tumor model. It will be presented by Rachelle Kosoff, Ph.D., Senior Scientist in Research at Advaxis."

“Our findings provide important insights into identifying those patients who are benefiting from these treatments,” said Dr. Hayes. “We’re pleased to share our findings with the rest of the community at the International Cancer Immunotherapy Conference as we continue our work to bring new treatment options to patients.”

If this helps make an already efficacious treatment better by predicting (hopefully) who may respond, think of the added benefit and value!
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ADXS News